{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-343428","form_type":"8-K","ticker":"CALC","cik":"0001534133","company_name":"CalciMedica, Inc.","filed_at":"2026-08-11T11:15:17+00:00","discovered_at":"2026-08-11T11:20:00.376294+00:00","generated_at":"2026-08-11T11:20:11.804181+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"CalciMedica Q2 net loss $7.7M, $49M financing, FDA aligns on AP trial","bullets":["Net loss Q2 2026 $7.7M ($0.45/share) vs $6.0M ($0.40) year ago.","Cash $18.6M at June 30, 2026; expected to fund operations into H2 2027.","Private placement up to ~$49M gross (~$15M upfront) to advance pulmonary hypertension program.","FDA aligned on Phase 2b design for Auxora in acute pancreatitis; primary endpoint new-onset severe respiratory failure.","Auxora Phase 1b PAH data and CM5480 IND submission both anticipated mid-2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-343428","json":"https://secwatch.observer/filing/0001193125-26-343428.json","markdown":"https://secwatch.observer/filing/0001193125-26-343428.md","text":"https://secwatch.observer/filing/0001193125-26-343428.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534133/000119312526343428/0001193125-26-343428-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534133/000119312526343428/ck0001534133-20260811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T11:20:11.804181+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}